- Home
- ADVM vs PNI Comparison
ADVM vs PNI Comparison
Compare ADVM & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- PNI
- Stock Information
- Founded
- ADVM 2006
- PNI 2002
- Country
- ADVM United States
- PNI United States
- Employees
- ADVM N/A
- PNI N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- PNI Trusts Except Educational Religious and Charitable
- Sector
- ADVM Health Care
- PNI Finance
- Exchange
- ADVM Nasdaq
- PNI Nasdaq
- Market Cap
- ADVM 66.3M
- PNI 77.2M
- IPO Year
- ADVM 2014
- PNI N/A
- Fundamental
- Price
- ADVM $3.02
- PNI $6.90
- Analyst Decision
- ADVM Strong Buy
- PNI
- Analyst Count
- ADVM 4
- PNI 0
- Target Price
- ADVM $19.75
- PNI N/A
- AVG Volume (30 Days)
- ADVM 84.1K
- PNI 26.4K
- Earning Date
- ADVM 11-03-2025
- PNI 01-01-0001
- Dividend Yield
- ADVM N/A
- PNI 4.76%
- EPS Growth
- ADVM N/A
- PNI N/A
- EPS
- ADVM N/A
- PNI N/A
- Revenue
- ADVM $1,000,000.00
- PNI N/A
- Revenue This Year
- ADVM $1,836.70
- PNI N/A
- Revenue Next Year
- ADVM N/A
- PNI N/A
- P/E Ratio
- ADVM N/A
- PNI N/A
- Revenue Growth
- ADVM N/A
- PNI N/A
- 52 Week Low
- ADVM $1.78
- PNI $6.03
- 52 Week High
- ADVM $8.56
- PNI $7.89
- Technical
- Relative Strength Index (RSI)
- ADVM 50.02
- PNI 75.01
- Support Level
- ADVM $2.93
- PNI $6.49
- Resistance Level
- ADVM $3.59
- PNI $6.93
- Average True Range (ATR)
- ADVM 0.22
- PNI 0.06
- MACD
- ADVM -0.02
- PNI 0.04
- Stochastic Oscillator
- ADVM 13.64
- PNI 92.31
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.